Testing a new drug combo for high-risk DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with DLBCL (a type of lymphoma) and have not had any treatment for it yet.
- You are able to swallow pills.
- You have a tumor or lymph node that is at least 1.5 cm on a CT scan and shows up on a PET scan.
- Your heart, kidney, and liver function meet certain lab levels, and you are generally in good health.
- You are not currently taking certain medications (like some antibiotics, antifungals, or antidepressants) that could interfere with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.